What is the recommended scoring system for predicting contrast-induced nephropathy (CIN) in patients with pre-existing kidney disease, diabetes, and heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mehran Risk Score for Contrast-Induced Nephropathy Prediction

The Mehran risk score is the validated and recommended scoring system for predicting contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention, particularly those with pre-existing kidney disease, diabetes, and heart failure. 1

Components of the Mehran Risk Score

The Mehran score incorporates eight clinical and procedural variables to stratify CIN risk 1:

  • Hypotension (systolic BP <80 mmHg for at least 1 hour requiring inotropic support or intra-aortic balloon pump within 24 hours peri-procedurally) 2
  • Intra-aortic balloon pump use 2
  • Congestive heart failure (NYHA class III/IV or history of pulmonary edema) 3
  • Age >75 years 2
  • Anemia (baseline hematocrit <39% for men, <36% for women) 4
  • Diabetes mellitus 5
  • Contrast media volume 5
  • Chronic kidney disease (baseline serum creatinine >1.5 mg/dL or eGFR <60 mL/min/1.73m²) 1, 6

Risk Stratification Categories

The score categorizes patients into four risk groups 2, 5:

  • Low risk: Score ≤5 (CIN risk ~7.5%)
  • Moderate risk: Score 6-10 (CIN risk ~14%)
  • High risk: Score 11-15 (CIN risk ~26%)
  • Very high risk: Score ≥16 (CIN risk ~57%)

Clinical Validation and Prognostic Value

The Mehran score predicts not only CIN development but also short- and long-term mortality and major adverse cardiovascular events. 2 In ST-elevation myocardial infarction patients undergoing primary PCI, mortality in the very high-risk group was more than 10-fold higher (HR 10.11,95% CI 4.83-21.1) compared to the low-risk group 2. The score maintains excellent discriminatory capacity with C-statistic values >0.8 and good calibration (Hosmer-Lemeshow p=0.7) in contemporary cohorts 5.

The score has been validated across multiple clinical settings including acute coronary syndromes 5, primary PCI for STEMI 2, and transcatheter aortic valve implantation 7, demonstrating consistent predictive accuracy over the past decade 5.

Alternative Simplified Approach

For rapid bedside assessment, the contrast volume-to-eGFR ratio (CV/GFR) provides comparable predictive accuracy to the Mehran score with greater simplicity. 4 A CV/GFR ratio >3.7 substantially increases CIN risk, particularly in patients with pre-existing renal impairment or diabetes 6. The CV/GFR ratio demonstrated similar area under the curve (0.79) compared to the Mehran score (0.65) in older adults undergoing coronary procedures 4.

Critical Caveats

Baseline chronic kidney disease remains the single most important risk factor, with patients having serum creatinine >2 mg/dL experiencing a 22.4% CIN incidence compared to 2.4% in those with normal function 6. Do not rely solely on baseline creatinine without calculating eGFR, as creatinine alone underestimates renal dysfunction, particularly in elderly patients and those with reduced muscle mass 3.

The score identifies patients requiring aggressive prophylactic measures including isotonic saline hydration (1.0-1.5 mL/kg/hour) for 3-12 hours before and 6-24 hours after contrast exposure, contrast volume minimization to <350 mL or <4 mL/kg, and use of low-osmolar or iso-osmolar contrast media 1, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.